The best use of adjuvant chemotherapy: New drugs and new use of "old" drugs Journal Article
| Author: | Hudis, C. |
| Article Title: | The best use of adjuvant chemotherapy: New drugs and new use of "old" drugs |
| Abstract: | Modern chemotherapy has diminished the risks of distant relapse and death in many subgroups of patients with early stage breast cancer. Although the initial trials relied on empirically designed regimens, studies are increasingly based on preclinical science and reflect the growing understanding of the molecular basis of cancer. Empiric clinical trials proved the worth of combination chemotherapy, the limited value of very long courses of treatment, and the benefits of adding first anthracyclines and then later taxanes. More recent trials have demonstrated the limits on empiric dose escalation and the benefits of optimized scheduling. Many trials are currently focused on novel targeted agents. Based on several decades of studies in thousands of women it is reasonable to consider a combination of chemotherapy agents for patients with hormone unresponsive or otherwise high-risk tumors. Anthracyclines and taxanes should be incorporated into the treatment plans of patients in the higher risk subsets and the specific regimens should be taken from the several randomized studies. When available, eligible patients should be enrolled on prospective clinical trials. © 2005 Elsevier Ltd. All rights reserved. |
| Keywords: | cancer survival; leukemia; clinical trial; doxorubicin; fluorouracil; cancer combination chemotherapy; dose response; drug efficacy; drug safety; treatment planning; capecitabine; gemcitabine; paclitaxel; cancer adjuvant therapy; chemotherapy, adjuvant; combined modality therapy; methotrexate; recurrence risk; antineoplastic agent; infection; breast cancer; blood toxicity; heart disease; antineoplastic combined chemotherapy protocols; drug administration schedule; cyclophosphamide; breast neoplasms; cancer mortality; docetaxel; randomized controlled trials; systematic review; adjuvant chemotherapy; epirubicin; taxane derivative; anthracycline derivative; trastuzumab; risk reduction; drug dose regimen; anthracyclines; dose calculation; meta analysis; granulocytopenia; hemopoietic growth factor; cardiomyopathy; taxanes; myelodysplasia |
| Journal Title: | Breast |
| Volume: | 14 |
| Issue: | 6 |
| ISSN: | 0960-9776 |
| Publisher: | Elsevier Inc. |
| Date Published: | 2005-12-01 |
| Start Page: | 570 |
| End Page: | 575 |
| Language: | English |
| DOI: | 10.1016/j.breast.2005.08.016 |
| PUBMED: | 16183287 |
| PROVIDER: | scopus |
| DOI/URL: | |
| Notes: | --- - "Cited By (since 1996): 4" - "Export Date: 24 October 2012" - "CODEN: BREAE" - "Source: Scopus" |
